Dr. Shibiao Wan is currently an Assistant Professor in the Department of Genetics, Cell Biology and Anatomy, and the Co-Director for the Bioinformatics and Systems Biology (BISB) PhD Program at University of Nebraska Medical Center (UNMC). He is also an Assistant Professor (courtesy) in the Department of Biostatistics at UNMC.
With more than 15 years of experience in machine learning, bioinformatics, and computational biology, Dr. Wan has published >50 articles in top-tiered journals such as Genome Research, Nature Communications, Science Advances, Circulation Research, Briefings in Bioinformatics, and Bioinformatics. Dr. Wan is the Editor-in-Chief for Current Proteomics, and an Editorial Board Member for a series of prestigious journals such as Briefings in Functional Genomics, Heliyon, BMC Bioinformatics, International Journal of Microbiology, PeerJ Computer Science, BioMed Research International, and Computational and Mathematical Methods, and a guest associate editor for multiple high-impact journals including Frontiers in Immunology, Frontiers in Cell and Developmental Biology, Frontiers in Pharmacology, Biology, Frontiers in Genetics, and Genes.
Dr Wan is a TPC member for >20 machine learning related international conferences including IEEE ICTAI. Dr. Wan is also a reviewer for >70 prestigious journals including Nature Biotechnology, Nature Methods, Nature Communications, Nature Computational Science, Science Advances, Nucleic Acids Research, Advanced Science, Cancer Research, Genome Biology, and Genome Medicine. Dr. Wan has received a number of accolades including the Springer Nature Editor of Distinction Award in 2025 by Springer Nature, the New Investigator Award in 2024 by UNMC, the FIRST Award in 2023 by Nebraska EPSCoR, the Outstanding Young Alumni Award in 2022 by HK PolyU as well as the Global Peer Review Awards (top 1%) in “Cross-Field” and “Biology and Biochemistry” in 2019 by Clarivate. Dr. Wan is a member of AACR, ISCB and ACM and an IEEE Senior Member.
Senior Lecturer in Pharmacology, University of Reading. British Neuroscience Association Local Group Representative. British Pharmacological Society (Member). UK Epilepsy Research Network (Interventions & Therapies CWG). Pharmacist (GPhC registered).
Investigating unmet clinical need in epilepsy with a specific focus on cannabinoid pharmacology using preclinical animal models and electrophysiological techniques supported by convention molecular and biochemical approaches.
Katrine Whiteson uses metagenomics, metabolomics, microbiology and ecological statistics to answer questions about how microbes and viruses affect human health. She studied Biochemistry at UC Berkeley (BA, 2000) and University of Chicago (PhD, 2007). During her PhD, Dr. Whiteson focused on the active site chemistry and DNA binding specificity of a site-specific recombinase from the class of proteins that enable the spread of antibiotic resistance genes. In 2008, she began a new job at the University of Geneva Hospitals with Dr. Jacques Schrenzel and Dr. Patrice Francois. This was an exciting era, just at the start of the Human Microbiome Project, for asking basic unanswered questions about the microbes and viruses inhabiting various niches of the human body. Dr. Whiteson focused on the oral microbial communities of healthy Europeans, and malnourished kids in Niger who develop a devastating facial gangrene known as noma. In 2011 she moved to Forest Rohwer’s lab at San Diego State, where she undertook breath and sputum metabolite analysis to better understand the activity of CF patient microbial communities from Dr. Doug Conrad’s Adult CF clinic at UCSD. Combining information about the genetic potential of a microbial community through DNA sequencing with the activity of the community by metabolite profiling is a powerful approach that Dr. Whiteson hopes to employ in future projects as she begins her own lab at University of California Irvine in Fall 2014.
Albert H.C. Wong is a neuroscientist and psychiatrist at the Centre for Addiction and Mental Health, and a Professor at the University of Toronto. He attended medical school at the University of Toronto, where he also completed specialty training in psychiatry and a PhD in neurobiology. Dr. Wong’s lab uses animal models and clinical studies to investigate genetic, epigenetic and developmental mechanisms of psychiatric disease. His areas of clinical expertise are in schizophrenia and brain stimulation.
Hao Wu is a patent scientist in an oncology-focused biotechnology company, Exelixis, Inc. She obtained her Ph.D. in molecular biology from Rowan University (previously known as the University of Medicine and Dentistry of New Jersey (UMDNJ) – Stratford Campus). With hands-on knowledge in various aspects of biology, including molecular biology, cell biology, biochemistry, immunology, neuroscience, oncology, Hao has worked on inventions spanning a broad range of technologies, for example, biologics, antibodies, biomarkers, diagnostics, cell therapy, gene therapy, and sequencing.
Bioinformatician currently at Memorial Loan Kettering Cancer Center with 10 years of experience in analyzing high-throughput genomic and proteomic data. I have a diverse background in handling raw exome & whole genome sequencing, RNA-Seq and ChIP-Seq data to identify genetic aberrations. Proficient in development and implementing pipelines and algorithms and post analysis of aberrations identified through individual assays to glean novel biological patterns. Led large-scalegenomic efforts such as MMRF CoMMpass trial, ICGC & TCGA.
Dr. Xin Zhang is Department Director and Principal Investigator of the Clinical Experimental Center at Jiangmen Central Hospital (China). He received his Ph.D. in Molecular Medicine from Sun Yat-sen University in 2016. Dr. Zhang is an enthusiastic, early career scientist involved in interdisciplinary training and has a strong biological background, including molecular pathology, molecular diagnostics, and molecular pharmacology. His current research interests mainly focus on the molecular mechanism of tumor recurrence and metastasis, clinical application of molecular diagnosis, and molecular pharmacological mechanism of traditional Chinese medicine in potential therapeutic application of cancer.